LTRN

Lantern Pharma Inc.

Insider Trades

NameValueActionPriceCurrent Price
Keyser D JeffreyDirector
$110k48.5k shares
BuyMay 12, 2026
$2.27
--
Schalop Lee TroyDirector
$110k48.5k shares
BuyMay 12, 2026
$2.27
--
Keyser D JeffreyDirector
$100k48.5k shares
BuyMay 12, 2026
$2.06
--
Schalop Lee TroyDirector
$100k48.5k shares
BuyMay 12, 2026
$2.06
--
Fletcher Aaron G.L.10 Percent Owner
$44k14.2k shares
SellJun 13, 2025
$3.09
--
Fletcher Aaron G.L.10 Percent Owner
$38k12.3k shares
SellJun 13, 2025
$3.09
--

News

gurufocus.comLantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancergurufocus.comJun 2businesswire.comLantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancerbusinesswire.comJun 2gurufocus.comLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLCgurufocus.comMay 19businesswire.comLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLCbusinesswire.comMay 19businesswire.comLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updatesbusinesswire.comMay 15